Zichron Yaakov, Israel

Dalit Barkan

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 2.9

ph-index = 1


Company Filing History:


Years Active: 2017-2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Dalit Barkan: Innovator in Cancer Treatment

Introduction

Dalit Barkan is a prominent inventor based in Zichron Yaakov, Israel. He has made significant contributions to the field of cancer research through his innovative patents. With a focus on apoptosis and differentiation of cells, Barkan's work aims to restore normal-like phenotypes in premalignant and malignant cells.

Latest Patents

Dalit Barkan holds 2 patents that showcase his groundbreaking research. His latest patents include the development of Apoptosis related protein in the TGF-beta signaling pathway (ARTS) mimetic compounds. These compounds serve as novel antagonists for XIAP and Bcl-2, inducing apoptosis and differentiation in cancer cells. Additionally, he has patented a method involving CD11b macrophages and their conditioned media for treating cancer and fibrosis. This innovative approach provides pharmaceutical compositions that utilize the conditioned medium of CD11b macrophages, offering new avenues for cancer treatment.

Career Highlights

Barkan is affiliated with Carmel—Haifa University Economic Corp Ltd., where he continues to advance his research. His work has garnered attention for its potential impact on cancer therapies, particularly in restoring normal cell functions in malignant conditions.

Collaborations

Dalit Barkan collaborates with notable colleagues, including Sarit Larisch and Odelya Gilon. Their combined expertise enhances the research efforts in the field of cancer treatment.

Conclusion

Dalit Barkan's innovative contributions to cancer research through his patents highlight his commitment to improving treatment options for patients. His work exemplifies the intersection of science and innovation, paving the way for future advancements in medical therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…